Successful treatment of peripartum cardiomyopathy: a case report
https://doi.org/10.15829/1728-8800-2024-4080
EDN: GLUOOA
Abstract
Peripartum cardiomyopathy is a rare disease that occurs in late pregnancy and early postpartum, manifesting as rapidly progressive heart failure. To save the mother’s life, quick diagnosis, correct routing and pathogenetic treatment is required. The demonstrated case shows a detailed childbirth situation, which could provoke peripartum cardiomyopathy in a 36-year-old woman with subclinical hypothyroidism, rapid recognition of the clinical situation with the correct treatment tactics, which helped not only to stabilize the patient’s condition, but also to completely restore the left ventricular contractile function. Practitioners are interested in following the tactics of drug treatment in the intensive care unit and further at the outpatient stage using a specific clinical example.
About the Authors
N. V. Korneeva
Far Eastern State Medical University
Russian Federation
Russian Federation
Khabarovsk
N. N. Mislimova
Sakhalin Regional Clinical Hospital
Russian Federation
Russian Federation
Yuzhno-Sakhalinsk
References
1. Filippov OS, Guseva EV, Pavlov KD. Global and Russian trends in Maternal mortality. Russian Journal of Human Reproduction. 2024; 30(1):100-8. (In Russ.) doi:10.17116/repro202430011100.
2. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364:k5287 doi:10.1136/bmj.k5287.
3. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017;19:1131-41. doi:10.1002/ejhf.780.
4. Veselovskaya NG, Chumakova GA, Nikolaeva MG, et al. Peripartum cardiomyopathy: pathogenesis, presentations, diagnosis, treatment, and prognosis. RMJ. 2021;10:44-8. (In Russ.)
5. Zazerskaya IE, Rudenko KA, Talanina YaS, et al. Risk Factors of Peripartum Cardiomyopathy. Doctor.Ru. 2021;20(6):20-5. (In Russ.) doi:10.31550/1727-2378-2021-20-6-20-25.
6. Bozkurt B, Colvin M, Cook J, et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134(23):e579-646. doi:10.1161/CIR.0000000000000455.
7. Irizarry OC, Levine LD, Lewey J, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol. 2017;2(11):1256-60. doi:10.1001/jamacardio.2017.3574.
8. McNamara DM, Elkayam U, Alharethi R, et al. IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905-14. doi:10.1016/j.jacc.2015.06.1309.
9. Tsoi IA, Abdullaev TA, Khudoyberganov OK, et al. Five-year prognosis of life in patients with peripartum cardiomyopathy. Russian Cardiology Bulletin. 2022;17(3):58-62. (In Russ.) doi:10.17116/Cardiobulletin20221703158.
Supplementary files
- Peripartum cardiomyopathy is a rare disease that develops at the end of pregnancy or in the first months after birth, which can quickly lead to death due to acute and rapidly progressing heart failure.
- Early diagnosis and correct tactics will save lives.
- To include this disease in the differential diagnostic list in complex clinical situations, main clinical manifestations and features of treatment tactics, which are presented in this clinical example, should be well known.
Review
For citations:
Korneeva N.V., Mislimova N.N. Successful treatment of peripartum cardiomyopathy: a case report. Cardiovascular Therapy and Prevention. 2024;23(7):4080. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4080. EDN: GLUOOA
Views:
1114
Email this article 
